Topical pimecrolimus for paediatric cutaneous mastocytosis

J. Mashiah, A. Harel, C. Bodemer, S. Hadj-Rabia, I. Goldberg, E. Sprecher, A. Kutz

Research output: Contribution to journalArticlepeer-review


Background: Most cases of paediatric cutaneous mastocytosis (CM) occur before the age of 2 years, and regression occurs in only 67% of children. Given the absence of any specific therapy, CM is usually treated symptomatically. A few publications have reported the beneficial effect of calcineurin inhibitors for CM. Aim: We sought to evaluate the clinical effectiveness and safety profile of topical pimecrolimus cream for the treatment of CM. Methods: We performed a retrospective study of all diagnosed cases of CM treated with topical pimecrolimus 1% cream between 2013 and 2015. All patients were evaluated in a paediatric dermatology unit of a tertiary medical centre. Epidemiological, clinical and treatment data, including effectiveness and safety, were reviewed. Results: In total, 18 children (11 male, 7 female; age range 3–42 months) with CM were evaluated. Of the 146 treated lesions, 39 (26.7%) disappeared and 98 (67%) faded or developed postinflammatory hyperpigmentation. Of the 119 papular lesions, 24 (16.4%) showed partial flattening and 56 (47%) became macular. Darier sign became negative in 14 (82%) of 17 patients. No topical or systemic complications were observed. Conclusions: Topical therapy with pimecrolimus 1% cream should be considered in the treatment of CM.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalClinical and Experimental Dermatology
Issue number5
StatePublished - Jul 2018


Dive into the research topics of 'Topical pimecrolimus for paediatric cutaneous mastocytosis'. Together they form a unique fingerprint.

Cite this